

TITLE: Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials[1]
TROPiCS-02 and EVER-132-002 are phase III randomized controlled trials (RCTs) comparing sacituzumab govitecan (SG) to treatment of physician’s choice
[1] Gluz O, Xu B, Nanda R, Dasgupta A, Kaushik A, Verret W, Sharma A, Singh B, Rugo HS. Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Ther Adv Med Oncol. 2025 Mar 14; 17:17588359251320285. doi: 10.1177/17588359251320285. PMID: 40093981; PMCID: PMC11907608.